{"id":379331,"date":"2020-11-12T06:48:27","date_gmt":"2020-11-12T11:48:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379331"},"modified":"2020-11-12T06:48:27","modified_gmt":"2020-11-12T11:48:27","slug":"annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/","title":{"rendered":"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BERWYN, Pa., Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog cohort of a chronic toxicology study of its lead therapeutic compound ANVS401 for the treatment of AD and PD, reporting no negative side effects.<\/p>\n<p align=\"justify\">The nine-month dog study was part of a series of animal toxicology studies, funded by a $1.9 million grant from the National Institutes of Health that began in the fourth quarter of 2019. The strong safety data corroborates the positive results from the Company\u2019s prior one-month safety studies in mice, rats, dogs, and humans and six-month study in rats. \u00a0\u00a0<\/p>\n<p align=\"justify\">Maria Maccecchini, Ph.D., CEO, commented, \u201cThe strong safety profile observed in ANVS401 in our chronic tox study in dogs is another important milestone for Annovis. Our chronic toxicology studies, which are key to enabling us to conduct long-term human studies, provide a solid foundation for ANVS401 as we continue to recruit and treat patients for our two active Phase 2a clinical trials. We intend to report interim data on our Phase 2a clinical trials in the first quarter of 2021.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>Annovis<\/strong><br \/>\n        <strong> Bio<\/strong>\n      <\/p>\n<p align=\"justify\">Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and Alzheimer\u2019s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company\u2019s website:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5KH3xwlsIJ0Dpsdy7teDZjFFYcYbsAKFNt71BPU42DnKcpPIbQdIdaotddhTPePXmd8G0AbQvIYor43O9g6UrfjrMyVxcsZhkFGVXRLrFiQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.annovisbio.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cforecast\u201d or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>Investor Relations:<\/p>\n<p>Dave Gentry, CEO<br \/>RedChip Companies Inc.<br \/>407-491-4498<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XLQNpQ4T4txQIxdFpavqLblhOVGHx4IIUkCyJVHPvM68q1SOLq3SpT3bhgYZqverm-XdScpnnqleIlLAFxT76g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dave@redchip.com<\/a><\/p>\n<p>SOURCE: Annovis Bio, Inc.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog cohort of a chronic toxicology study of its lead therapeutic compound ANVS401 for the treatment of AD and PD, reporting no negative side effects. The nine-month dog study was part of a series of animal toxicology studies, funded by a $1.9 million grant from the National Institutes of Health that began in the fourth quarter of 2019. The strong safety data corroborates the positive results from the Company\u2019s prior one-month safety studies in mice, rats, dogs, and humans and six-month study in rats. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379331","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog cohort of a chronic toxicology study of its lead therapeutic compound ANVS401 for the treatment of AD and PD, reporting no negative side effects. The nine-month dog study was part of a series of animal toxicology studies, funded by a $1.9 million grant from the National Institutes of Health that began in the fourth quarter of 2019. The strong safety data corroborates the positive results from the Company\u2019s prior one-month safety studies in mice, rats, dogs, and humans and six-month study in rats. &hellip; Continue reading &quot;Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T11:48:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases\",\"datePublished\":\"2020-11-12T11:48:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/\"},\"wordCount\":571,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/\",\"name\":\"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=\",\"datePublished\":\"2020-11-12T11:48:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases - Market Newsdesk","og_description":"BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog cohort of a chronic toxicology study of its lead therapeutic compound ANVS401 for the treatment of AD and PD, reporting no negative side effects. The nine-month dog study was part of a series of animal toxicology studies, funded by a $1.9 million grant from the National Institutes of Health that began in the fourth quarter of 2019. The strong safety data corroborates the positive results from the Company\u2019s prior one-month safety studies in mice, rats, dogs, and humans and six-month study in rats. &hellip; Continue reading \"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T11:48:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases","datePublished":"2020-11-12T11:48:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/"},"wordCount":571,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/","name":"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=","datePublished":"2020-11-12T11:48:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOSMzODI0MDIyIzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-reports-positive-results-from-final-phase-of-1-9m-nih-funded-chronic-toxicology-study-for-its-lead-compound-for-the-treatment-of-alzheimers-and-parkinsons-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379331"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379331\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}